Short Summary
Glaxo Group Limited successfully concluded its trademark infringement litigation against Park Pharmaceuticals through an amicable settlement. The court decreed the suit based on the compromise, which required Park Pharmaceuticals to cease using deceptively similar marks like AQUAMENTIN and CETUM, acknowledge Glaxo's ownership of AUGMENTIN and CEFTUM, change product branding (to CLAVPARK and PARXETIL), destroy all infringing materials, and pay a settlement amount of Rs. 1,50,000.
Detailed Summary
In the fiercely competitive pharmaceutical industry, a brand name can be the difference between a trusted cure and a questionable substitute. When smaller players attempt to mimic the look and sound of established pharma giants, the legal system becomes the frontline defense for patient safety and brand integrity. The clash between Glaxo Group Limited and Park Pharmaceuticals is a textbook example of how trademark battles can end not with a bang, but with a binding handshake — and why that handshake matters more than founders might think.
Glaxo Group Limited, a globally recognized pharmaceutical powerhouse, built its reputation on trusted brands that doctors and patients rely on every day. Among its prized trademarks were AUGMENTIN, a flagship antibiotic, and CEFTUM, another well-established pharmaceutical product. These marks represented years of research, marketing investment, and consumer trust.
Park Pharmaceuticals, a smaller player in the market, allegedly began marketing products under the names AQUAMENTIN and CETUM. To the casual observer, these names sounded strikingly similar to Glaxo's established brands — close enough to raise serious questions about whether consumers could tell them apart at the pharmacy counter. Glaxo Group Limited, along with a co-plaintiff, filed suit against Park Pharmaceuticals and an associated party, alleging trademark infringement and seeking to protect its valuable brand portfolio.
Glaxo Group Limited argued that Park Pharmaceuticals' use of AQUAMENTIN and CETUM constituted deceptive similarity to its registered trademarks AUGMENTIN and CEFTUM. The core of Glaxo's complaint was that such close imitations could mislead consumers, dilute the distinctiveness of its brands, and unfairly divert market share built on decades of reputation.
Rather than letting the dispute drag through years of litigation, both sides chose to negotiate. The legal friction centered on whether Park Pharmaceuticals' marks were genuinely independent creations or calculated attempts to capitalize on Glaxo's goodwill. The settlement discussions ultimately addressed every point of contention — from the infringing names themselves to the physical materials bearing them.
On 19 November 2020, the court formally decreed the suit in terms of the compromise reached between the parties. The settlement was not a quiet handshake — it was a court-ordered mandate with teeth. Under the agreed terms, Park Pharmaceuticals was required to:
- Immediately cease using the marks AQUAMENTIN and CETUM, or any other marks deceptively similar to Glaxo's AUGMENTIN and CEFTUM.
- Formally acknowledge Glaxo's exclusive ownership of the AUGMENTIN and CEFTUM trademarks.
- Rebrand its products under entirely new names: CLAVPARK and PARXETIL.
- Destroy all infringing materials, including packaging, labels, and promotional assets bearing the disputed marks.
- Pay Glaxo a settlement amount of Rs. 1,50,000.
By incorporating the compromise into the official court decree, the settlement gained the full binding force of a judicial order — making any future violation enforceable as contempt of court rather than a mere contractual breach.
For founders and IP professionals, this case delivers a powerful lesson: settlement is not a sign of weakness — it is a strategic tool. When trademark disputes are resolved through compromise and that compromise is formally decreed by the court, the resulting agreement carries the weight of a judicial order. This means undertakings to cease use, rebrand, destroy infringing goods, and pay compensation are not just promises — they are court-mandated obligations. Startups and growing businesses should recognize that protecting a famous brand is not just about winning courtroom battles; sometimes, the most effective victory is a well-structured settlement that locks in accountability and clears the path forward.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in trademark matters before Delhi High Court - Orders. Understanding the court's reasoning in Glaxo Group Limited vs Park Pharmaceuticals is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Mahesh Namkeen Pvt. Ltd.vsOm Prakash Nebhwani (Trading as: Mahesh Matar Namkeen)
Mahesh Namkeen Pvt. Ltd., a Lucknow-based company engaged in manufacturing namkeens and snacks since 1983 under the trademark 'MAHESH' (with parrot device), sued Om Prakash Nebhwani for trademark infringement and passing off. The defendant, who is the nephew of the plaintiff's director and had prior knowledge of the mark, adopted the identical 'MAHESH' mark with parrot/peacock device for his own namkeen business in Jaipur. The defendant's defense was struck off for non-filing of written statement. The court found the plaintiff's mark to be distinctive, well-established, and a well-known trademark, and held that the defendant's use constituted slavish copying amounting to infringement and passing off.
Ms Pas AgrovsM/S Krbl Limited & Anr
Ms Pas Agro has filed a petition under Section 124(1)(b)(ii) of the Trademarks Act challenging the Commercial Court's order dismissing its application to frame a preliminary issue on the invalidity of KRBL's registered trademark 'INDIA GATE' (application no. 599833). The underlying suit CS (COMM) 78/2025 was filed by KRBL against Pas Agro. The Delhi High Court issued notice, permitted deletion of respondent no.2, and granted time for filing reply and rejoinder. The substantive question of whether a preliminary issue on trademark invalidity should be framed remains pending.
Cryogas Equipment Private LimitedvsInox India Limited & Ors.
The Supreme Court disposed of a miscellaneous application seeking extension of time for the trial court to decide Trademark Suit No. 3 of 2019 between Cryogas Equipment Private Limited and Inox India Limited. As a last opportunity, the Court granted an additional six months to the concerned court to decide the suit, while expressly warning that no further extension would be entertained. The underlying dispute concerns trademark rights in the cryogenic/industrial gas equipment sector.
Mankind Consumer Products Private LimitedvsAlaina Healthcare Private Limited & A. Menarini India Private Limited
Mankind Consumer Products, the registered proprietor of the trademark ACNESTAR (Reg. No. 1352577 in Class 5) since 2005, sued Alaina Healthcare and A. Menarini India for using the marks ACNE SCAR/ACNE+SCAR/ACNESCAR on their acne scar serum product HEXILAK. The court found a prima facie case of deceptive similarity, noting that the dominant feature 'ACNE' was common and the suffix 'STAR' vs 'SCAR' was insufficient to distinguish the marks, especially given the identical trade channels and consumer class. The court granted an interim injunction in favour of the plaintiff while allowing defendant no. 2 a two-month period to recall existing stock from the trade.
Healthium Medtech Limited (earlier Healthium Medtech Private Limited)vsThe Registrar of Trade Marks, Chennai
Healthium Medtech Limited filed a writ petition seeking a mandamus to compel the Registrar of Trade Marks to expeditiously dispose of Opposition No. 1027536 filed by Glenmark Pharmaceuticals against Healthium's trademark application No. 4270882 for the 'Healthium' device mark in Classes 05 and 10. The petitioner complained that despite evidence having been adduced, the opposition proceedings remained pending without a final hearing. The Madras High Court allowed the writ petition and directed the Registrar to hear both parties and dispose of the opposition on merits within four weeks.
CavinKare Private LimitedvsMaha Aqua, Trading As Mahalakshmi Aqua
CavinKare Private Limited filed a trademark infringement suit against Maha Aqua (trading as Mahalakshmi Aqua) seeking a permanent injunction to restrain the defendant from using the mark 'MAA' or any deceptively similar mark in respect of goods in Class 32. The plaintiff relies on its registered trademarks 'MAA' under Nos. 1109946 and 6453733. The Court, after issues were framed and affidavits of admission/denial filed, approved a Joint Case Management Schedule suggested by both parties and set timelines for completion of evidence and oral arguments.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.